FINAXIONResearch
Finaxion Research · RSI 14: buy oversold (30/70) · single stocks · Recomputed 2026-09-10

Does RSI 14: buy oversold (30/70) work on ABBV?

RSI 14: buy oversold (30/70) does not beat buy-and-hold on ABBV: -7.1 points a year over 14 years.

Total return
446.0%
Buy and hold
×13
CAGR
13.3%
Sharpe
0.56
Max drawdown
-37.0%
Trades
32
Out of sample
—
Years
14
1×6.8×2014201520162017201820192020202120222023202420252026
StrategyABBV

Findings

  1. RSI 14: buy oversold (30/70) does not beat buy-and-hold on ABBV: -7.1 points a year over 14 years.
  2. Against the S&P 500 over the same window: -1.6 points a year.
  3. Total return +446.0% versus ×13 for buy-and-hold, with 32 trades.
  4. Maximum drawdown -37.0%.
  5. It did not beat before 2019 and started afterwards.
  6. It ranks #38 of 235 markets for this strategy by annual excess over the S&P 500.

Findings derived from the full panel. Each carries its number and its denominator; the computations are reproducible with artifact 4941ce415f47.

Exactly what was tested

RSI(14) crosses below 30 → entry. RSI(14) crosses above 70 → exit. Next-close execution.

How to read it

The verdict compares the strategy with buying and holding ABBV over the same window, with round-trip costs per asset class. “Out of sample” is walk-forward: the rule is fit on one stretch and judged on the next. A result that beats in the full sample but not out of it is overfit. Full methodology in the protocol. How we test.

Open this backtest with its trades   Trades (CSV)

Every strategy on ABBV → · Full page for RSI 14: buy oversold (30/70) →

How to cite

Finaxion Research (2026). Does RSI 14: buy oversold (30/70) work on ABBV?. Daily backtest 1962-01-01–2026-08-31, artifact 4941ce415f47. https://finaxion.app/en/research/rsi-14-oversold/abbv

Not a recommendation. Past performance does not guarantee future results.